Amneal Pharmaceuticals, Inc. Class A Common Stock - Asset Resilience Ratio
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) has an Asset Resilience Ratio of 0.05% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check asset allocation strategy of Amneal Pharmaceuticals, Inc. Class A Com to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2015–2024)
This chart shows how Amneal Pharmaceuticals, Inc. Class A Common Stock's Asset Resilience Ratio has changed over time. See AMRX net asset quality score to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Amneal Pharmaceuticals, Inc. Class A Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AMRX company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.87 Million | 0.05% |
| Total Liquid Assets | $1.87 Million | 0.05% |
Asset Resilience Insights
- Limited Liquidity: Amneal Pharmaceuticals, Inc. Class A Common Stock maintains only 0.05% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Amneal Pharmaceuticals, Inc. Class A Common Stock Industry Peers by Asset Resilience Ratio
Compare Amneal Pharmaceuticals, Inc. Class A Common Stock's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867 |
Drug Manufacturers - Specialty & Generic | 0.76% |
|
Eris Lifesciences Limited
NSE:ERIS |
Drug Manufacturers - Specialty & Generic | 0.58% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Lotus Pharmaceutical Co Ltd
TW:1795 |
Drug Manufacturers - Specialty & Generic | 0.49% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
|
Sun Pharma Advanced Research Company Limited
NSE:SPARC |
Drug Manufacturers - Specialty & Generic | 0.64% |
Annual Asset Resilience Ratio for Amneal Pharmaceuticals, Inc. Class A Common Stock (2015–2024)
The table below shows the annual Asset Resilience Ratio data for Amneal Pharmaceuticals, Inc. Class A Common Stock.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.05% | $1.87 Million | $3.50 Billion | -0.01pp |
| 2023-12-31 | 0.06% | $2.20 Million | $3.47 Billion | +0.02pp |
| 2022-12-31 | 0.05% | $1.82 Million | $3.80 Billion | +0.02pp |
| 2021-12-31 | 0.03% | $1.17 Million | $3.94 Billion | -0.01pp |
| 2020-12-31 | 0.04% | $1.70 Million | $4.01 Billion | +0.01pp |
| 2019-12-31 | 0.03% | $1.12 Million | $3.67 Billion | -0.02pp |
| 2018-12-31 | 0.05% | $2.14 Million | $4.35 Billion | -0.09pp |
| 2017-12-31 | 0.14% | $1.85 Million | $1.34 Billion | -0.22pp |
| 2016-12-31 | 0.36% | $4.35 Million | $1.22 Billion | -0.13pp |
| 2015-12-31 | 0.49% | $4.98 Million | $1.01 Billion | -- |
About Amneal Pharmaceuticals, Inc. Class A Common Stock
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms … Read more